Developmental and Epileptic Encephalopathies

Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...

BOSTON, August 6, 2026 Praxis Precision Medicines reported its second quarter 2026 financial results, highlighting continued regulatory progress for...

VALBY, Denmark, July 20, 2026 H. Lundbeck A/S has reached a major clinical development milestone with the last patient...

CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics has unveiled encouraging late-breaking Phase IIa clinical results for its investigational immunotherapy...

BOSTON, June 29, 2026 Praxis Precision Medicines announced that the U.S. Food and Drug Administration (FDA) has extended the...